The results demonstrated that patients in the high-PLEKHA4 group achieved higher TIDE scores, as well as T cell exclusion scores and dysfunction scores (Figure 12C), indicating that patients with higher PLEKHA4 expression could achieve less sensitivity to ICBs treatment because of T cell exclusion and immune dysfunction. The gene discussed is PLEKHA4; the disease is immune system disorder.